Sector
PharmaceuticalsOpen
₹745Prev. Close
₹750Turnover(Lac.)
₹138.16Day's High
₹753.7Day's Low
₹74052 Week's High
₹862.652 Week's Low
₹570Book Value
₹105.46Face Value
₹1Mkt Cap (₹ Cr.)
2,169.89P/E
45.72EPS
16.44Divi. Yield
0.61Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 2.89 | 2.92 | 2.92 | 2.92 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 285.6 | 287.85 | 262.2 | 212.64 |
Net Worth | 288.49 | 290.77 | 265.12 | 215.56 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 332.84 | 261.47 | 223.17 | 206.88 |
yoy growth (%) | 27.29 | 17.16 | 7.87 | 12.2 |
Raw materials | -140.18 | -117.07 | -95.63 | -83.37 |
As % of sales | 42.11 | 44.77 | 42.84 | 40.29 |
Employee costs | -41.7 | -39.36 | -33.85 | -29.67 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 81.9 | 34.45 | 31.08 | 35.09 |
Depreciation | -3.66 | -4.35 | -2.9 | -2.04 |
Tax paid | -20.71 | -9.37 | -12.9 | -11.98 |
Working capital | 78.27 | -1.63 | 12.83 | 6.67 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 27.29 | 17.16 | 7.87 | 12.2 |
Op profit growth | 143.39 | 8.16 | -5.46 | -4.82 |
EBIT growth | 137.64 | 11.08 | -11.4 | 1.35 |
Net profit growth | 143.94 | 25.58 | -8.37 | -2.76 |
Particulars (Rupees in Crores.) | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 | Mar-2013 |
---|---|---|---|---|---|
Gross Sales | 231.7 | 194.52 | 174.1 | 147.46 | 144.07 |
Excise Duty | 10.61 | 9.05 | 8.32 | 7.05 | 7.4 |
Net Sales | 221.1 | 185.47 | 165.78 | 140.41 | 136.66 |
Other Operating Income | 2.88 | 1.28 | 0.79 | 1.32 | 0.99 |
Other Income | 7.52 | 5.68 | 4.53 | 2.94 | 4.26 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,813.45 | 157.05 | 4,32,948 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,876.7 | 85.94 | 1,57,872.84 | 518 | 0.5 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,447.3 | 27.59 | 1,16,809.04 | 1,178.16 | 0.9 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,345.85 | 68.85 | 1,12,638.04 | 460 | 0.84 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,641.85 | 52.98 | 1,06,197.5 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
S Sambhuprasad
Independent Non Exe. Director
V Raja
Independent Non Exe. Director
Muralidharan Swayambunathan
Independent Non Exe. Director
Meena Lochani Raghunathan
Non Executive Director
Ramaa Prabhakar Arikirevula
Company Sec. & Compli. Officer
M Srinivasan.
Non Executive Director
G Raghavan
Independent Director
V Nagaraj
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Amrutanjan Health Care Ltd
Summary
Amrutanjan Health Care Limited (AHCL) was incorporated on September 9, 1936 in Chennai, Tamil Nadu. The Chennai-based Amrutanjan manufactures bulk drugs and drug intermediates like theophylline, based on in-house research. Three plants have been set up in the Alandur industrial belt near Chennai to produce these products. It recently entered into a joint venture with Welsh firm Cardiff Chemicals to manufacture pheromones (a type of agrochemicals) at Cuddalore. Pheromones have found wide application as pesticides and are used on cotton crops. The Company is engaged into manufacture, supply, sale of products in pain management, congestion management, beverages & hygiene and services in pain management.Amrutanjan has an agreement with a company in Philadelphia, US, to supply custom-made chemicals for exotic applications like the genetic manipulation of biological matter. It has introduced some new range of products like Pep Pill, Amrutanjan gripe water sans alcohol, Amrutanjan Maha Strong, etc. Plans are afoot to introduce analgesic and antipyretic tablets. The company also plans to launch sanitary napkins soon. The company has approached the US FDA for approval and clearance to sell its new drugs in US. During 1996-97, it has introduced a new product called Cold Snap Gel and also a mint called tingle. Company having two subsidiary companies viz. Amrutanjan Drugs & Chemicals Ltd having holding stake 99.80% & Amrutanjan Finance Ltd, having holding stake is 57.26%.Company has take
Read More
The Amrutanjan Health Care Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹750.55 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Amrutanjan Health Care Ltd is ₹2169.89 Cr. as of 13 Dec ‘24
The PE and PB ratios of Amrutanjan Health Care Ltd is 45.72 and 7.30 as of 13 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Amrutanjan Health Care Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Amrutanjan Health Care Ltd is ₹570 and ₹862.6 as of 13 Dec ‘24
Amrutanjan Health Care Ltd's CAGR for 5 Years at 11.00%, 3 Years at -6.01%, 1 Year at 27.08%, 6 Month at -0.41%, 3 Month at -4.45% and 1 Month at 12.54%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice